Trevi Therapeutics, Inc.

NASDAQ•TRVI

執行長: Ms. Jennifer L. Good

板塊: Healthcare

行業: Biotechnology

上市日期: 2019-05-07

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

聯絡資訊

195 Church Street, 16th Floor, New Haven, CT, 06510, United States

203-304-2499

www.trevitherapeutics.com

市值

$1.83B

本益比 (TTM)

-48.6

股息率

52周最高

$14.39

52周最低

$5.38

52周範圍

99%

排名62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

基於 9 年期基本面

疲弱 • 1.9 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2017-2025

財務儀表板

Q4 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.06+0.00%

近4季度走勢

自由現金流

$5.85M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Net Loss Narrows Significantly Net loss decreased $5.2M to $42.8M for 2025, reflecting reduced R&D spending versus prior year.

Strong Cash Position Maintained Cash and marketable securities reached $188.3M by year-end 2025, funding operations into 2028.

Positive Cough Trial Results Phase 2b CORAL trial achieved primary endpoint showing significant 24-hour cough frequency reduction.

Phase 3 Trials Scheduled FDA alignment secured; first pivotal Phase 3 trial for IPF-related cough set to initiate Q2 2026.

關注風險

Continued Operating Losses Expected Significant losses incurred since inception; substantial additional capital required to fund operations beyond 2028.

Sole Product Candidate Dependency Business success entirely dependent on Haduvio development, approval, and commercialization success across indications.

Clinical Trial Design Uncertainty Trial outcomes are uncertain; regulatory changes or enrollment difficulties could delay approval or increase costs.

Opioid Class Label Warning Nalbuphine carries opioid class warning; potential restrictive marketing/distribution regulations could harm profitability.

未來展望

Initiate Pivotal Phase 3 Studies Plan to initiate two pivotal Phase 3 trials for IPF chronic cough starting Q2 2026, running in parallel.

Expand Chronic Cough Development Adaptive Phase 2b trials planned for non-IPF ILD and RCC indications starting second half of 2026.

Complete NDA Supportive Testing Progressing remaining Phase 1 NDA supportive studies, including respiratory safety assessment, targeting completion mid-2026.

Maintain Intellectual Property Focus remains on maintaining, expanding, and protecting proprietary patent portfolio across key territories globally.

同行對比

營業收入 (TTM)

NVAX

$1.12B

+64.7%

ARDX

$407.32M

+22.1%

SNDX

$172.35M

+627.8%

毛利率 (最新季度)

SNDX

102.3%

-13.9pp

NBTX

100.0%

+0.0pp

IMTX

100.0%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
TERN	$4.75B	-51.0	-20.0%	0.1%
SYRE	$4.17B	-153.8	-29.4%	0.0%
SNDX	$2.15B	-7.4	-206.6%	65.4%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月6日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料